The Flotek PREPA Contract That Lasted Two Weeks

On August 3, 2026, Flotek Industries announced it had been awarded a 10-year contract worth approximately $400 million in potential revenue with the Puerto Rico Electric Power Authority. The stock surged. The company raised its full-year guidance. Wall Street was energized by the idea that this small, turnaround energy-services company had just locked in a decade-long revenue stream.

Fourteen days later, the contract was terminated. Not paused. Not delayed. Erased.

The Financial Oversight and Management Board for Puerto Rico — a federally appointed body with real authority over the island's finances — revoked its approval of the deal and told PREPA to end it. Then a short-seller report came out explaining why: the company that originally held the contract slot, Enchanted Rock, LLC, had never actually authorized its participation. Its name and signature had been used without permission. The matter was referred for criminal prosecution.

Flotek's stock dropped 20% on August 17, then another 5.7% and 6.9% over the next two trading days. Multiple law firms filed class action lawsuits covering the August 3 through August 17 class period.

Here's the thing that doesn't immediately show up in the headlines: the PREPA contract was never part of Flotek's guidance. The company had made zero revenue from it. The core business — which is growing fast — was never at risk. And that is the structural reason why this story matters differently than it looks.

The deal that appeared from nowhere

Flotek Industries is a Houston-based specialty chemistry and data analytics company with about $860 million in market capitalization. The parent company, ProFrac Holdings, owns 61% of Flotek and provides a revenue floor through minimum-purchase commitments in the chemistry business. That's a structural relationship worth knowing: most of Flotek's traditional chemistry revenue comes from related parties. It's stable — but concentrated.

The interesting part of the business is the pivot that's been unfolding. Flotek has been transitioning from a cyclical chemicals supplier to a high-margin data-as-a-service platform for the energy sector. It acquired PWRtek in April 2025, and that technology became the engine of a Data Analytics segment that now generates 71% gross margins and has overtaken chemistry as the company's largest profit contributor.

On August 3, Flotek announced the PREPA deal: a 10-year agreement to deploy PWRtek systems alongside power generation equipment for a 400-megawatt natural gas-fired project. At full deployment, it would generate about $40 million in annual revenue, or $400 million over the life of the contract. It was supposed to begin in Q4 2026.

Except Flotek hadn't actually won this contract in the ordinary sense. It had been substituted into it. On July 31 — just three days before the announcement — PREPA consented to replacing Enchanted Rock, LLC with Flotek under the existing agreement. Flotek went public with the news as "Flotek Awarded 10-Year Contract." The press release language was accurate enough — Flotek was awarded the contractual role — but the provenance of the contract was not the provenance of a contract that Flotek had earned.

And Enchanted Rock, it turns out, was a ghost. Or at least a name being used by someone who hadn't authorized it.

The plumbing of the collapse

Here's the sequence, which matters because the timeline is the entire class action:

• August 3: Flotek announces the PREPA contract. Stock surges.
• August 4: Q2 earnings are released — revenue up 70% to $99.4 million, EPS of $0.26 versus $0.13 expected. Management raises full-year 2026 revenue guidance to $340-$350 million (from $270-$290 million) and adjusted EBITDA guidance to $47-$51 million (from $36-$41 million). The PREPA contract is explicitly excluded from these numbers.
• August 11: On the earnings call, management describes the PREPA deal at length. CEO Ryan Gillis Ezell paints a picture of a growing power services pipeline exceeding $1 billion in potential value. CFO J. Bond Clement notes the contract adds $400 million to backlog and that the total contracted backlog now exceeds $500 million.
• August 13: Puerto Rico authorities refer the procurement process to the Department of Justice and federal investigators.
• August 14: The Oversight Board revokes approval under PROMESA Section 204 and directs PREPA to terminate.
• August 17: Wolfpack Research publishes its short report. PREPA tells all consortium parties to halt work. Stock falls 20%.
• August 18: Flotek issues an update, reaffirming guidance. Stock falls 5.7%.
• August 19: PREPA delivers formal termination notice. Stock falls another 6.9%.

The class action complaints allege that Flotek's statements between August 3 and August 17 were materially misleading because the company knew or should have known that the Enchanted Rock authorization problems threatened the contract. In its August 18 filing, Flotek acknowledged it had been "advised that questions existed regarding the authorization of certain signatures" before joining the project, though it said these issues were "fully vetted through the procurement process."

That phrase — "advised that questions existed" — is the sentence the plaintiffs will live in for the next couple of years. Whether it constitutes a failure to disclose depends on how a court interprets the boundary between "vetted" and "known to be defective." Flotek apparently believed PREPA and the Third-Party Procurement Office's approval was sufficient. It turned out not to be.

The actual business, stripped of the noise

This is where the classification question becomes material. Because the PREPA contract was never included in Flotek's guidance, the company has a legitimate argument that the core investment case was never built on it. The $340-$350 million revenue guidance and the $47-$51 million EBITDA guidance were raised on August 4 — before the collapse — and they excluded the PREPA deal. Flotek reaffirmed that guidance on August 18, after the Oversight Board voted, and again after the formal termination on August 19.

So the question for an investor watching this stock isn't whether the PREPA contract is real. It's not. The question is whether the rest of the business is real.

And the numbers say yes, with some structural caveats:

Q2 2026 revenue was $99.4 million, up 70% from the prior year. Net income jumped to $10 million, up 463% year-over-year. The Data Analytics segment — which is what investors are actually buying here — delivered record quarterly revenue. At the same time, chemistry segment revenues from external customers dropped 33% in Q1, highlighting that the traditional business continues to lean heavily on related-party ProFrac transactions.

The valuation tells part of the story too. Flotek trades at about 23 times trailing earnings, 2.9 times trailing sales, and roughly 24 times EV/EBITDA. The forward P/E is around 60. That's not a beaten-down turnaround stock. That's a stock that's already pricing in growth — a growth story built on the Data Analytics segment expanding its margin contribution and on international chemistry sales, not on Puerto Rico power contracts that vanish in two weeks.

What the market is actually pricing

The stock dropped from roughly $35-37 in mid-August to $23.72 as of August 31. That's a sharp fall, but the shares are still up about 38% year-to-date and roughly 100% over the trailing twelve months. The 52-week low is $10.95. The stock was a runner before the PREPA announcement, not just because of it.

The class action period — August 3 to August 17 — captures only the brief window when investors bought the stock believing the PREPA contract was genuine. Investors who bought outside that window, or who bought on the Q2 earnings beat, aren't covered. The lawsuit is narrow by design. It's about whether Flotek misled investors about this specific contract during this specific period.

But the real investor question is broader: what does this episode tell you about the company's risk profile going forward?

The structural risk

Flotek is a small company — $860 million market cap — pursuing an aggressive transformation. The Data Analytics segment is the genuine story: it grew 295% year-over-year in Q1, reached 71% gross margins by Q3 2025, and now contributes more than half the company's gross profit. The PWRtek platform is real, the patents are real, and the Q2 results confirm the growth trajectory.

But there are genuine structural risks that have nothing to do with Puerto Rico:

The ProFrac concentration is real. Sixty-one percent ownership plus related-party minimum purchase obligations means that Flotek's chemistry revenue — still the largest revenue segment — is effectively backed by a single counterparty. If ProFrac's own business deteriorates, the revenue floor becomes a revenue ceiling.

The cash flow picture has timing risks. Management acknowledged that H1 2026 consumes significant working capital to stabilize Middle East operations, and payment terms in international markets are extending by 20-25 days. Growth is real but cash is lagging.

The company raised full-year guidance excluding Puerto Rico, but it also assumed zero Q4 revenue from its Montana power services contract — a known potential headwind. The pipeline is "at its highest level in company history" at over $1 billion in potential value, but pipelines are not contracts, and the PREPA episode is a reminder of the gap between the two.

The lawsuit itself is a distraction cost at this point. Discovery will consume management time and legal expense through much of 2027, but it won't change the revenue numbers unless it settles for something material. Most securities class actions of this size settle in the tens of millions, which is meaningful but not company-ending for an $860 million business.

Where it leaves you

The PREPA contract was a flash in the pan — a $400 million backlog number that existed for two weeks and then dissolved into criminal referrals and securities lawsuits. The market overreacted on the way up (as markets do with small-cap turnaround stories hitting a milestone) and overreacted on the way down (as they also do).

What matters for someone watching this stock is the separation between the noise and the mechanism. The Data Analytics segment is the machine that matters: real margins, real growth, real Q2 results that beat estimates by 100% on EPS. The chemistry business is the weight: cyclically exposed and concentrated, but structurally stabilized by the ProFrac relationship. The PREPA deal was neither. It was a contract that existed on paper for 16 days.

Flotek is trading at a multiple that assumes the growth story works. The Q2 results say it does. The PREPA episode says the execution environment is rougher and less controlled than a press release suggests. That's a risk to price in — not by writing the whole thing off, but by understanding which parts of this company's story are built on contracts and which parts are built on momentum.